Gate Bioscience, a Brisbane, CA-based biotechnology company, announced on October 5, 2026 an expansion of its collaboration and license agreement with Eli Lilly and Company to discover, develop, and commercialize molecular gate therapeutics.

Expanded Multi-Year Agreement Adds New Targets

The expansion adds one target to the companies' existing work, with the opportunity to add a second target. The multi-year expansion builds on the companies' 2025 agreement to use Gate's Molecular Gate drug discovery engine to design molecular gate medicines for Lilly targets.

The programs leverage Gate's Molecular Gate drug discovery engine to identify medicines capable of eliminating specific difficult-to-drug proteins in diseases of high unmet medical need.

Financial Terms of the Deal

Under the terms of the multi-year research collaboration, Gate will receive an upfront payment and a subsequent payment upon selection of the second target, plus research funding to support its discovery efforts.

Gate is also eligible to receive payments upon achievement of certain preclinical, clinical, and commercial milestones, as well as tiered royalties on global net sales. The total potential value of the agreement could exceed USD 870 million, contingent on the achievement of milestones.

Lilly will receive an exclusive, worldwide license to research, develop, commercialize, and otherwise exploit products arising from the collaboration for the selected targets.

Leadership Perspective

"Our existing collaboration with Lilly has shown that our discovery engine can systematically deliver selective molecular gates against difficult-to-drug proteins," said Jordi Mata-Fink, Ph.D., co-founder and CEO of Gate Bioscience.

"Expanding into an additional therapeutic area reflects Lilly's confidence in that engine and in the team behind it. Lilly's expertise has accelerated our progress, and the collaboration strengthens the wholly owned portfolio of molecular gate medicines we continue to build alongside it."

Division of Responsibilities

Gate will lead discovery efforts under the agreement, applying its Molecular Gate Discovery Platform to selected targets, while continuing to advance its wholly owned portfolio of molecular gate medicines toward the clinic.

Lilly will be responsible for later-stage preclinical development, clinical development, manufacturing, and commercialization of medicines arising from the collaboration.

About Molecular Gates

Molecular gates are orally available small molecule drugs that eliminate a target protein potently and selectively by blocking the protein's progress through the secretory channel Sec61, leading to degradation of the target protein.

Among the approximately 4,000 targets of molecular gates are many high-value targets in the areas of immunology, neuroscience, cardiometabolic health and other diseases, which currently have no therapies or require injectables to eliminate the target protein.

About Gate Bioscience

Gate Bioscience is a biotechnology company developing molecular gates, a new class of small molecule medicines that eliminate disease-causing proteins at their source.

The company's proprietary Molecular Gate Discovery Platform enables the rapid and repeatable discovery of selective molecular gates against difficult-to-drug proteins across multiple therapeutic areas.

The platform integrates a privileged library of molecular gate compounds, a suite of secretion-focused assays and technologies, and deep expertise in the biology of the secretory pathway.

Gate is backed by Forbion, Versant Ventures, Andreessen Horowitz (a16z), GV, ARCH Venture Partners, and Eli Lilly and Company.

Stay Ahead of Every Project, Tender, and Contract Across the World

How much could your business grow if you knew about major projects before your competitors did? With infrastructure and industrial activity accelerating across markets in the world, the real advantage lies not in reacting to news headlines but in having structured, verified project intelligence delivered to your screen first.

Every stage of a project's lifecycle creates opportunities; a tender notice today becomes a supply contract tomorrow, and a completed project signals the next round of expansion and demand. The companies that thrive are the ones that see this entire pipeline in one place, without piecing together scattered reports or chasing unreliable sources.

The Global Project Tracking (GPT) platform by Blackridge Research consolidates project data across the world into a single, easy-to-navigate intelligence hub, so your team can move faster, bid smarter, and plan with confidence.

• Upcoming Projects

• Tender Notices

• Contract Awards

• Projects Under Construction

• Completed Projects

Book a Free Demo today and see how the Global Project Tracking (GPT) platform by Blackridge Research turns worldwide data into your competitive edge.